Target intelligence / Profile preview

Blood coagulation system

Molecular classification
Other (a multi-protein pathway/system; includes serine proteases, cofactors, glycoproteins)
01

Overview

The blood coagulation system is a physiological network responsible for hemostasis by converting soluble fibrinogen to insoluble fibrin through a tightly regulated cascade of enzymatic reactions[1][3][5][7]. It includes the intrinsic (contact activation), extrinsic (tissue factor), and common pathways, each involving multiple serine proteases (termed coagulation factors, designated by Roman numerals I-XIII), co-factors, glycoproteins, and modulatory proteins. The system’s balance is essential for effective blood clotting to repair vascular injury and for preventing excess clot formation leading to diseases like thrombosis or bleeding disorders[2][3][5]. The blood coagulation system as a whole does not function as a single therapeutic target but is instead a critical physiological process comprised of many individual molecular targets (for example, thrombin, factor Xa, tissue factor, and others), each of which can be a distinct therapeutic target[1][2][3]. If you meant to refer to a specific molecule within the coagulation cascade (such as "thrombin" or "factor Xa"), please specify so detailed, structured data can be provided for that individual target.

Other names
Blood clotting systemCoagulation cascadeHemostatic systemClotting system
02

Mechanism of action

Anticoagulation (inhibition of coagulation factors, such as direct or indirect thrombin inhibition, factor Xa inhibition, vitamin K antagonism), Procoagulant therapies (replacement of factors, e.g., recombinant factor VIII/IX), Antifibrinolytics (inhibition of fibrin degradation)

03

Biological functions

HemostasisBlood clot formationWound healingMaintenance of vascular integrityControl of bleeding
04

Disease associations

Cardiovascular diseaseThrombosisHemorrhagic disorders (such as hemophilia)StrokeVenous thromboembolismLiver diseaseDisseminated intravascular coagulationOther
05

Safety considerations

Bleeding (hemorrhagic risk)Thrombosis (increased clotting risk)Drug-drug and drug-food interactions (especially with vitamin K antagonists like warfarin)Monitoring challenges (narrow therapeutic index of some drugs)Allergy/anaphylaxis to factor replacementsLiver dysfunction affecting synthesis of coagulation proteins
06

Interacting drugs

Warfarin

6 more in the full profile.

07

Biomarkers

Prothrombin time (PT)activated partial thromboplastin time (aPTT)Fibrinogen levelsD-dimerThrombin timePlatelet countIndividual factor assays (e.g., FVIII, FIX)

Beyond the preview

Go deeper on Blood coagulation system.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blood coagulation system.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call